Blog

August 26, 2021

PPMD Invests $350,480 in Myosana Therapeutics to Support Non-Viral Gene Therapy Development

Parent Project Muscular Dystrophy is excited to announce a $350,480 programmatic investment in Myosana Therapeutics, Inc. (Myosana) to support the company’s early-stage development of a non-viral gene therapy delivery platform aiming to slow skeletal muscle…

Learn More

PPMD Begins Process to Update Community-Led Duchenne Guidance for FDA

PPMD takes every action necessary to ensure therapies are developed efficiently and that they include the voice of the community. In 2014, we came together as a community, creating and submitting to the FDA the…

Learn More

Recently Reported Updates from PPMD’s 2021 Virtual Annual Conference

PPMD’s 2021 Virtual Annual Conference: Recently Reported Updates As a new addition to PPMD’s 2021 Virtual Conference, PPMD invited industry partners to share new data with the community live during the Conference in a series…

Learn More

PPMD Is Moving to Washington, DC!

PPMD’s Main Office is Moving to Washington, DC! When Parent Project Muscular Dystrophy started in 1994, formed by a small group of parents and grandparents out of Ohio, we knew that one of our first…

Learn More

Rewatch PPMD’s 2021 Virtual Annual Conference

Did You Miss PPMD’s 2021 Virtual Annual Conference? PPMD’s 2021 Virtual Annual Conference was incredible with close to 2,000 families, care providers, researchers, scientists, and industry partners joining us for four days of informative updates…

Learn More

PPMD & Jesse’s Journey Award $172,000 (CAD) Clinical Fellowship in Duchenne Endocrinology & Bone Fragility

Parent Project Muscular Dystrophy (PPMD) and Jesse’s Journey today announced a collaborative research award of $172,000 (CAD) in support of a two-year Clinical Fellowship in Duchenne Endocrinology and Bone Fragility. The award will sponsor the fellowship of…

Learn More

Take Part in the Duchenne Steroid Patient Experience Survey

Patient experience data is a critical tool for advancing drug development in Duchenne and for regulatory decision making. Steroids have been part of care standards for over two decades, however, there is a lack of…

Learn More

C-Path Opens Access to Duchenne Regulatory Science Consortium (D-RSC) Database

PPMD is proud to be an original funder and continued supporter of the Duchenne Regulatory Science Consortium (D-RSC) database, which includes data from Duchenne clinical trials, natural history studies, and clinical data collections. With the strength…

Learn More

Webinar Q&A: Gene Therapy – Turning Obstacles into Possibilities

Last week, PPMD held a webinar to discuss the lessons learned in Gene Therapy, current challenges for our community, and what the future holds for these promising treatments. After opening with an insightful presentation from…

Learn More

WATCH: Gene Therapy – Turning Obstacles into Possibilities (Webinar Recording)

On April 20, 2021, PPMD’s Pat Furlong & Eric Camino were joined by Drs. Nagaraju and Shieh for an interactive panel discussion on the lessons learned in Gene Therapy, current challenges for our community, and…

Learn More

Join Our Mailing List